Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Mi‐Suk Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5817-2444; OpenAlex author ID A5003581837. Sources: OpenAlex.

Their work

Papers
20 (first author 7, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 5 papers · 2022: 4 papers · 2023: none · 2024: 5 papers · 2025: 1 paper

Papers 20

  1. Early response evaluation using CT and CA 19-9 in patients with pancreatic cancer of all stages undergoing first-line FOLFIRINOX treatment. Last author DOI 10.1016/j.pan.2025.02.007↗
  2. Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70363↗
  3. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin leve… Co-author DOI 10.1038/s41416-023-02474-w↗
  4. Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum … Co-author DOI 10.1038/s41416-023-02520-7↗
  5. Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Ca… Co-author DOI 10.1200/cci.24.00021↗
  6. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy. First author DOI 10.4143/crt.2023.586↗
  7. Regional lymph node metastasis detected on preoperative CT and/or FDG-PET may predict early recurrence of pancreatic adenocarcinoma after curative resection. First author DOI 10.1038/s41598-022-22126-y↗
  8. Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19-9. Last author DOI 10.1148/radiol.212236↗
  9. Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer. Co-author DOI 10.3390/cancers14194672↗
  10. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.5009/gnl20301↗
  11. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. Last author DOI 10.1007/s00261-020-02661-w↗
  12. Systematic review and meta-analysis of diagnostic performance of CT imaging for assessing resectability of pancreatic ductal adenocarcinoma after neoadjuvant t… First author DOI 10.1007/s00261-021-03198-2↗
  13. Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. Co-author DOI 10.1177/0284185120917118↗
  14. [Radiologic Evaluation for Resectability of Pancreatic Adenocarcinoma]. First author DOI 10.3348/jksr.2021.0019↗
  15. The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma. First author DOI 10.3348/kjr.2019.0862↗
  16. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing bloc… Co-author DOI 10.1016/j.pan.2020.05.017↗
  17. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. Co-author DOI 10.4251/wjgo.v12.i2.182↗
  18. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.4143/crt.2017.404↗
  19. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A sing… Co-author DOI 10.1053/j.seminoncol.2018.01.001↗
  20. Correlation between 18F-fluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer. First author DOI 10.1007/s12149-014-0833-x↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Seungmin Bang · 12 shared papers, 2017–2025 · strength 1.85
  2. Hee Seung Lee · 11 shared papers, 2017–2025 · strength 1.64
  3. Seung‐seob Kim · 9 shared papers, 2020–2025 · strength 1.55
  4. Jung Hyun Jo · 9 shared papers, 2017–2025 · strength 1.34
  5. Si Young Song · 7 shared papers, 2017–2024 · strength 0.88
  6. Moon Jae Chung · 7 shared papers, 2017–2024 · strength 0.85
  7. Jeong Youp Park · 7 shared papers, 2017–2024 · strength 0.85
  8. Ho Kyoung Hwang · 5 shared papers, 2021–2024 · strength 0.78
  9. Chang Moo Kang · 5 shared papers, 2019–2024 · strength 0.74
  10. Seung Woo Park · 6 shared papers, 2017–2024 · strength 0.73
  11. Myeong‐Jin Kim · 3 shared papers, 2019–2024 · strength 0.46
  12. Shin Hye Hwang · 2 shared papers, 2021 · strength 0.42
  13. Huapyong Kang · 4 shared papers, 2017–2022 · strength 0.42
  14. Sunyoung Lee · 2 shared papers, 2021–2022 · strength 0.36
  15. Hyun Kyung Yang · 2 shared papers, 2021–2024 · strength 0.35
  16. Jae Bock Chung · 2 shared papers, 2017–2025 · strength 0.34
  17. Chang‐Hwan Park · 2 shared papers, 2024 · strength 0.33
  18. Jae Woo Kim · 2 shared papers, 2024 · strength 0.33
  19. Eui Joo Kim · 2 shared papers, 2024 · strength 0.33
  20. Hong Sik Lee · 2 shared papers, 2024 · strength 0.33
  21. Y. Choi · 2 shared papers, 2024 · strength 0.33
  22. Hyungsik Roger Moon · 2 shared papers, 2024 · strength 0.33
  23. Eun Kwang Choi · 2 shared papers, 2024 · strength 0.33
  24. Dong Uk Kim · 2 shared papers, 2024 · strength 0.33
  25. Seung Ok Lee · 2 shared papers, 2024 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.